Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med's Innovative Drug Portfolio: Eight Candidates in 31 Trials

publication date: Aug 2, 2017
While announcing 2017 first-half financial results, Hutchison China MediTech (Chi-Med) provided a broad overview of its wide-ranging innovative drug portfolio. Comprised of eight drug small-molecule candidates, the portfolio is currently involved in 31 clinical trials. There are many signs of progress: earlier this year, Chi-Med filed its first NDA, a request for China approval of fruquintinib, a VEGFR inhibitor, as a treatment for colorectal cancer. Chi-Med also started its first global Phase III registration trial (for savolitinib), and it has five other pivotal Phase III studies underway with three more close to starting. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here